X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (346) 346
index medicus (346) 346
male (195) 195
hematology (183) 183
female (182) 182
aged (179) 179
middle aged (176) 176
oncology (143) 143
waldenstrom macroglobulinemia - mortality (127) 127
waldenstrom macroglobulinemia - drug therapy (115) 115
adult (114) 114
prognosis (98) 98
aged, 80 and over (85) 85
treatment outcome (81) 81
rituximab (78) 78
waldenstrom macroglobulinemia - diagnosis (78) 78
chronic lymphocytic-leukemia (72) 72
waldenstrom macroglobulinemia - therapy (65) 65
waldenstrom macroglobulinemia (63) 63
multiple-myeloma (61) 61
antineoplastic agents - therapeutic use (57) 57
consensus panel recommendations (57) 57
waldenstrom macroglobulinemia - pathology (55) 55
2nd international workshop (53) 53
waldenstroms macroglobulinemia (52) 52
lymphoma (49) 49
survival analysis (49) 49
survival rate (49) 49
antineoplastic combined chemotherapy protocols - therapeutic use (46) 46
phase-ii trial (44) 44
retrospective studies (44) 44
macroglobulinemia (43) 43
waldenström macroglobulinemia (43) 43
therapy (42) 42
abridged index medicus (41) 41
waldenstrom macroglobulinemia - complications (41) 41
disease-free survival (40) 40
survival (40) 40
waldenstrom macroglobulinemia - immunology (40) 40
lymphoplasmacytic lymphoma (38) 38
multiple myeloma (37) 37
risk factors (37) 37
waldenstrom's macroglobulinemia (37) 37
diagnosis (35) 35
monoclonal gammopathy (35) 35
waldenstrom macroglobulinemia - genetics (35) 35
follow-up studies (32) 32
lymphomas (32) 32
bortezomib (31) 31
cancer (31) 31
fludarabine (31) 31
hematology, oncology and palliative medicine (31) 31
chemotherapy (30) 30
waldenstrom macroglobulinemia - blood (30) 30
waldenström's macroglobulinemia (28) 28
igm monoclonal gammopathy (27) 27
age factors (26) 26
disease progression (25) 25
immunoglobulin m - blood (25) 25
transplantation (25) 25
care and treatment (24) 24
international workshop (24) 24
non-hodgkins-lymphoma (24) 24
undetermined significance (24) 24
vidarabine - analogs & derivatives (24) 24
mutation (23) 23
prognostic-factors (23) 23
cyclophosphamide (22) 22
ibrutinib (22) 22
leukemia (22) 22
antineoplastic combined chemotherapy protocols - adverse effects (21) 21
l265p somatic mutation (21) 21
stem-cell transplantation (21) 21
clinical trials as topic (20) 20
features (20) 20
recurrence (20) 20
antibodies, monoclonal - therapeutic use (19) 19
medicine, general & internal (19) 19
time factors (19) 19
waldenstrom macroglobulinemia - epidemiology (19) 19
antineoplastic agents - adverse effects (18) 18
bone marrow - pathology (18) 18
treatment (18) 18
antibodies, monoclonal, murine-derived (17) 17
classification (17) 17
cooperative-oncology-group (17) 17
dexamethasone (17) 17
diagnosis, differential (17) 17
disease (17) 17
immunoglobulin m (17) 17
management (17) 17
mantle cell lymphoma (17) 17
patients (17) 17
stem cell transplantation (17) 17
multiple myeloma - mortality (16) 16
myd88 l265p (16) 16
prognostic factors (16) 16
antineoplastic combined chemotherapy protocols - administration & dosage (15) 15
combined modality therapy (15) 15
cyclophosphamide - administration & dosage (15) 15
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (381) 381
German (4) 4
Italian (3) 3
French (2) 2
Russian (2) 2
Spanish (2) 2
Polish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 6, pp. 584 - 586
Journal Article
Leukemia, ISSN 0887-6924, 08/2013, Volume 27, Issue 8, pp. 1722 - 1728
Journal Article
Journal Article
Journal Article
Blood, ISSN 0006-4971, 2009, Volume 113, Issue 16, pp. 3673 - 3678
We report the long-term outcome of a multicenter, prospective study examining fludarabine and rituximab in Waldenstrom macroglobulinemia (WM). WM patients with... 
MULTIPLE-MYELOMA | PROGNOSTIC FACTORS | MANTLE-CELL LYMPHOMA | TREATMENT RECOMMENDATIONS | CHRONIC LYMPHOCYTIC-LEUKEMIA | PHASE-II | FOLLICULAR LYMPHOMA | LOW-GRADE | HEMATOLOGY | 3RD INTERNATIONAL WORKSHOP | COOPERATIVE-ONCOLOGY-GROUP | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Neoplasms, Second Primary - mortality | Waldenstrom Macroglobulinemia - diet therapy | Pneumonia - mortality | Time Factors | Neoplasms, Second Primary - chemically induced | Pneumonia - chemically induced | Myelodysplastic Syndromes - chemically induced | Neutropenia - mortality | Female | Waldenstrom Macroglobulinemia - mortality | Leukemia, Myeloid, Acute - chemically induced | Neutropenia - chemically induced | Antibodies, Monoclonal, Murine-Derived | Vidarabine - adverse effects | Rituximab | Survival Rate | Thrombocytopenia - chemically induced | Vidarabine - analogs & derivatives | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Myelodysplastic Syndromes - mortality | Thrombocytopenia - mortality | Aged | Vidarabine - administration & dosage | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 19, pp. 3276 - 3282
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2016, Volume 23, Issue 1, pp. 60 - 66
Journal Article
Journal Article